Physician profile
Thomas J Murphy
NPI 1699776724
$1,443.70
in general payments reported to CMS, 2019-2025
24 companies · $346 in 2025
The $346 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.78 · 2020: $48.94 · 2021: $13.41 · 2022: $153 · 2023: $367 · 2024: $416 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $193.28 | 2022-2025 | |
| Lilly USA, LLC | $189.34 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $142.23 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $125.63 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $104.42 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $88.36 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $78.41 | 2023-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $52.33 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $51.85 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbvie INC. | $47.51 | 2021-2025 | |
| Dexcom, INC. | $44.32 | 2023-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $39.60 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $39.10 | 2023 | |
| Amarin Pharma, INC. | $36.43 | 2019-2020 | |
| Boston Scientific Corporation | $29.98 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.55 | 2024-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $28.38 | 2019-2025 | Heplisav-B |
| Sanofi Pasteur INC. | $24.38 | 2025 | |
| Shield Therapeutics INC | $20.43 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $19.53 | 2023 | Spravato |
| Sumitomo Pharma America, INC. | $18.25 | 2024 | Gemtesa |
| Tempus Ai, INC | $17.40 | 2025 | Tempus Pixel |
| Ironshore Pharmaceuticals INC. | $12.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.